Ageing, lifestyle changes, limited access to healthcare and socio-economic challenges have contributed heavily to the rising mortality rate among Kenya's elderly population, raising concerns about the ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Intensive blood pressure control for adults with hypertension and high cardiovascular risk can reduce the risk of mild ...

The LungFit PH device was approved ini 2022 by the U.S. Food and Drug Administration and the European Union to treat PPHN.

An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...

Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of ...